Segra International Corp. is pleased to announce a new partnership with cannabis brand Compound Genetics. Under the agreement Segra will partner with San Francisco based Node Labs LLC to introduce a variety of forward-thinking cultivars from Compound Genetics, and other top genetics brands, to Canadian and International growers via Segra’s plant tissue culture production nursery. Cultivar menu development is underway with releases anticipated in early 2023. Tissue culture nursery stock plantlets will be distributed under both exclusive and limited license agreements to growers globally.
“We are thrilled for this opportunity to introduce so many more people around the world to the exceptional Compound Genetics brand experience through this collaborative partnership,” said Jamie Blundell, CEO of Segra. “Our tissue culture nursery process, quality control systems, and sales network makes us the ideal partner for both exceptional breeders like Compound and top licensed producers globally.”
Lauren Avenius, CEO of Node Labs commented, “We could not be happier to be partnering with Segra. Their commitment to the plant and excellence mirrors the best in cannabis. The launch of Compound Genetics in Canada through Segra's tissue culture nursery will allow our premium family of cultivars to reach outside the US and be accessed by cultivators and consumers worldwide, all with the same quality and trust that our customers have come to expect from Node Labs.”
This new partnership provides a lucrative opportunity for growers to bring official Compound Genetics cultivars to their respective markets, and in many cases exclusive access. Segra’s clean stock tissue culture plantlets provide growers piece of mind that the plants will arrive free of any detectable pests or pathogens.
For more information:
Segra International Corp.